- Home
- ยป
- What We Offer
- »
- Pharmaceutical Vaccine
Pharmaceutical Vaccine
Anti Rabies Vaccine
Dose/Strength (ex. 1 mg or 1 ml) | 0.5 ml |
Type | Anti - rabies vaccine |
Packaging Type | Bottle |
Packaging Size | 100 ml |
Dosage Form | Injection |
Usage | Clinical, Hospital |
Composition per single dose:
- Freeze-dried vaccine: One immunizing dose contains the protective activity of equal to or greater than 2.5 International Units (IU) even after exposure at 37-degree centigrade for one month.
- Rabies Virus (L.Pasteur 2061/Vero) propagated on Vero cell line, inactivated with beta-propiolactone. Thiomersol 0.015% added as the preservative
- Maltose q.s. per immunizing dose
- Human Serum Albumin q.s. per immunizing dose.
- Sodium Chloride (0.9%) for Injection I.P.- 0.5 ml.
The Neomycin, Kanamycin and Polymyxin - B sulphate used in the cell and virus cultures are eliminated to the greatest extent during purification procedures and cannot be detected in the final vaccine.
Chicken Pox Vaccine
Dose | 1ml-5ml |
Packaging Type | Glass Bottle |
Injectable Form | Solution |
Application | Anti Infective & Common Disease Medicines, Analgesics and Pain Relief Medicines |
Injection Site | Intramuscular |
Medicine Type | Allopathic |
Packaging Size | 100 ml |
Usage | Hospital, Clinical |
Chickenpox vaccine is recommended for the following:
- All children younger than age 13 years (one dose at 12–15 months and a second dose at age 4–6 years);
- Everyone age 13 years and older who has never had chickenpox (two doses, given 4–8 weeks apart);
Almost all (97%) children between age 12 months and 12 years develop immunity to the disease after one dose of vaccine. For older children and adults, an average of 78% develop immunity after one dose and 99% develop immunity after the recommended two doses.
Meningitis Vaccine
Packaging Type | Bottle |
Dose/Strength (ex. 1 mg or 1 ml) | 5mg/ml |
Form | Injection |
Packaging Size | 100 ml |
Usage | Hospital, Clinical |
Drug name | Meningitis |
MMR Vaccine
Packaging Type | Bottle |
Dose/Strength (ex. 1 mg or 1 ml) | 5mg/ml |
Packaging Size | 100 ml |
Usage | Clinical, Hospital |
Generic Name | MMR |
Form | Injection |
The vaccine is a mixture of three live attenuated viruses, administered via injection. The shot is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5). The second dose is a dose to produce immunity in the small number of persons (2–5%) who fail to develop measles immunity after the first dose. In the United States, the vaccine was licensed in 1971 and the second dose was introduced in 1989. It is widely used around the world; since introduction of its earliest versions in the 1970s, over 500 million doses have been used in over 60 countries. As with all vaccinations, long-term effects and efficacy are subject to continuing study. The vaccine is sold by Merck as M-M-R II, Glaxo SmithKline Biologicals as Priorix, Serum Institute of India as Tresivac and Sanofi Pasteur as Trimovax.
It is usually considered a childhood vaccination. However, it is also recommended for use in some cases of adults with HIV.
Influenza Vaccine
Packaging Type | Bottle |
Dose/Strength (ex. 1 mg or 1 ml) | 1mg/ml |
Packaging Size | 10 ml |
Usage | Hospital, Clinical |
Form | Injection |
Dose type | Allopathic |
Effective Vaccines
Packaging Type | Bottle |
Dose/Strength (ex. 1 mg or 1 ml) | 10 ml |
Packaging Size | 100 ml |
Usage | Clinical, Hospital |
Form | Injection |
Type | Vaccination |
Vaccines and biological products such as anti toxins and sera. Various vaccines offered by us include anti rabies vaccine, hepatitis B vaccine, oral polio vaccine, vaccines and serum, influenza vaccine, meningitis vaccine and chicken pox vaccine. Other vaccines offered by us
- DPT Vaccine
- MMR Vaccin
- TD Vaccine
- Chicken Pox Vaccine
- Trivalent Vaccine
- Quadrivalent Vaccines/Pentavalent Vaccines
Oral Polio Vaccine
Three or more spaced doses of OPV are required to generate adequate levels of seroconversion. The action of oral polio vaccine (OPV) is two-pronged. OPV produces antibodies in the blood ('humoral' or serum immunity) to all three types of poliovirus, and in the event of infection, this protects the individual against polio paralysis by preventing the spread of poliovirus to the nervous system.
OPV strains also produce a local immune response in the lining ('mucous membrane') of the intestines - the primary site for poliovirus multiplication. The antibodies produced there inhibit the multiplication of subsequent infections of 'wild' (naturally occurring) virus. This intestinal immune response to OPV is probably a reason why mass campaigns with OPV have been shown to stop person-to-person transmission of wild poliovirus. In very rare cases, the administration of OPV results in vaccine-associated paralysis associated with a reversion of the vaccine strains to the more neurovirulent profile of wild poliovirus. In a few instances, such vaccine strains have become both neurovirulent and transmissible and have resulted in infectious poliomyelitis..
Bromobutyric Acid
Grade Standard | Reagent Grade, Analytical Grade |
Physical State | Liquid |
Usage | Laboratory, Commerical |
Packaging Type | Bottle |
TD Vaccine
DPT Vaccine
DPT (also DTP and DTwP) refers to a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis (whooping cough) andtetanus. The vaccine components include diphtheria and tetanus toxoids, and killed whole cells of the organism that causes pertussis (wP).
DTaP and Tdap refer to similar combination vaccines in which the pertussis component is acellular.
Also available is the DT or TD vaccine, which lacks the pertussis component.